Gossamer Bio GOSS 深 沪
等待开盘 10-14 09:30:00 美东时间
9.76
+0.480
+5.17%
华盛通- 最 高10.0343
- 今 开9.83
- 成交量 47.86万股
- 最 低 9.26
- 昨 收 9.28
- 总市值 5969.60万
- 52周最高 309.60
- 市盈率 静 --
- 换手率 7.83%
- 52周最低 8.99
- 委 比 72.64%
- 总股本 611.64万
- 历史最高 2172.00
- 量 比 2.13
- 振 幅 8.34%
- 历史最低 9.104
- 每 手 1
- 风险率 98.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Chardan Capital Initiates Coverage On Gossamer Bio with Buy Rating, Announces Price Target of $160
Chardan Capital analyst Andreas Argyrides initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Buy rating and announces Price Target of $160.
今天 03:31
Gossamer Bio Regains Nasdaq Listing Bid Price Compliance
The latest update is out from Gossamer Bio ( ($GOSS) ). On September 25, 2026, ...
09-29 05:15
Gossamer Bio submits NDA for seralutinib for pulmonary arterial hypertension
Gossamer Bio (GOSS) has submitted an NDA to the US FDA seeking approval of seralutinib for pulmonary arterial hypertension (PAH). The application is supported by data from the phase 3 PROSERA study, e...
09-24 06:16
美股大行评级 | 麦当劳目标价遭下调至320美元！现价仍有近3成上涨空间；戴尔、迈威尔、微软齐获机构看好
今日重点评级关注：HC Wainwright & Co.：维持Gossamer Bio"买入"评级，目标价从2美元升至90美元；巴克莱：维持Ultragenyx Pharmaceutical"超配"评级，目标价从32美元升至35美元
09-22 16:25
Gossamer Bio Defendants Move to Dismiss Securities Lawsuit Over PROSERA Trial Disclosures
Gossamer Bio, Inc. ($GOSS) and two of its executives have asked a federal court...
09-17 17:54
Gossamer Bio Announces 1-For-80 Reverse Stock Split, Effective September 10
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, today ...
09-09 21:07
Gossamer Bio announces up to $250M private placement
Gossamer Bio (GOSS) announced on Friday a private placement expected to provide up to approximately $250M in gross proceeds. The financing includes $150M of committed capital, with approximately $25M ...
08-21 21:19
Gossamer Bio Secures Major Seralutinib Regulatory Financing Deal
Gossamer Bio ( ($GOSS) ) has shared an announcement. On August 20, 2026, Gossam...
08-21 20:29
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
Piper Sandler Maintains Overweight on Gossamer Bio, Lowers Price Target to $4
Piper Sandler analyst Yasmeen Rahimi maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and lowers the price target from $15 to $4.
08-15 00:35
